Companies · Biotech
Africa · Biotech
Diligence memoA one-page analyst read on Yemaachi — recommendation, valuation, rhythm, risks.→Yemaachi looks over-valued against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
Yemaachi is one of 233 Biotech companies tracked from Africa. By capital raised it ranks in the upper tier (ahead of 76% of sector peers), and in the upper tier by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
Ghanaian cancer research and diagnostics company Yemaachi Biotech has closed a US$3 million seed round to advance its mission of diversifying precision oncology globally.
Ghanaian cancer research and diagnostics company Yemaachi Biotech has closed a US$3 million seed round to advance its mission of diversifying precision oncology globally.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.
Round size and date are reported; the stage label is inferred from round size (latest is Seed — a $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 233 companies in Biotech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 76% of sector peers (real $). Modeled value above 83% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #1 of 6.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Yemaachi this company | Seed | $3.0M | $51.0M | 3.87× |
| INVO Bioscience, Inc. | Seed | $7.8M | $29.2M | 2.21× |
| General Genomics Inc. | Seed | $4.0M | $14.1M | 1.07× |
| MET Biotechnology Inc. | Seed | $2.0M | $12.3M | 0.93× |
| J3 Bioscience, Inc. | Seed | $5.5M | $7.4M | 0.56× |
| Psycheceutical Bioscience, Inc. | Seed | $7.3M | $492K | 0.04× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Seed | $3.0M | 2022-03-25 | $15.0M | $51.0M | 45% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Yemaachi is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| OneThree Biotech, Inc. | Biotech | Seed | $2.8M | $124.4M | same sector · same stage |
| KelSie Biotech Corp | Biotech | Seed | $3.3M | $40.2M | same sector · same stage |
| Phloem Biotech, Inc. | Biotech | Seed | $2.7M | $118.7M | same sector · same stage |
| Cen Biotech Inc | Biotech | Seed | $2.6M | $117.1M | same sector · same stage |
| Ambra Bioscience LLC | Biotech | Seed | $3.8M | $46.6M | same sector · same stage |
| Meridian Biotech, LLC | Biotech | Seed | $3.9M | $88.0M | same sector · same stage |
| Sixfold Bioscience Inc. | Biotech | Seed | $2.3M | $70.2M | same sector · same stage |
| General Genomics Inc. | Biotech | Seed | $4.0M | $14.1M | same sector · same stage |
See where Yemaachi sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Yemaachi, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.